Clinical trial
Study Evaluating the Combination of Etanercept and Methotrexate in Rheumatoid…
NCT00252668 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00252668 |
|---|---|
| Title | Study Evaluating the Combination of Etanercept and Methotrexate in Rheumatoid Arthritis Subjects |
| Official title | An Open-Label, Multicentre, Extension Study of the Combination of Etanercept and Methotrexate in Rheumatoid Arthritis Subjects |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Drug |
| Interventions | Etanercept, Methotrexate |
| Enrollment | 300 |
| Start date | Jun 1, 2004 |
| Completion | Sep 1, 2005 |
| First posted | Nov 11, 2005 |
| Last update posted | May 18, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: